FDA approves first at-home HIV test
FDA recently approved the first over-the-counter test for HIV, providing a confidential in-home testing option for the virus that causes AIDS, with results in as little as 20 minutes.
FDA recently approved the first over-the-counter test for human immunodeficiency virus (HIV), providing a confidential in-home testing option for the virus that causes acquired immune deficiency syndrome (AIDS), with results in as little as 20 minutes.
“This new in-home rapid test-the same test doctors have used for years-will help individuals at risk for HIV who otherwise may not test in a professional or clinical setting," said Douglas A. Michels, president and CEO of OraSure Technologies, the manufacturer of the OraQuick In-Home HIV Test.
The test is designed to detect the presence of antibodies to HIV-1 and HIV-2 through an oral fluid swab of the upper and lower gums inside the mouth. The fluid sample is then put into a developer vial for 20 to 40 minutes.
According to FDA, The Centers for Disease Control and Prevention estimates that 1.2 million people in the United States are living with HIV infection, and about 1 in 5 are not aware that they are infected. This test has the potential to identify large numbers of people with previously undiagnosed HIV infections who might not otherwise use traditional screening methods at clinics and other centers.
FDA stresses that outcomes are not absolute, especially when exposure may have occurred within the past 3 months. Clinical studies have indicated that the home test could result in 1 false negative for every 12 test results and 1 false positive for every 5,000 test results in uninfected individuals.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More
